Terms: = Skin cancer AND NCOA4, RP11-481A12_4, 8031, ENSG00000138293, PTC3, ELE1, Q13772, RFG, DKFZp762E1112, ARA70 AND Clinical Outcome
363 results:
1. clinical determinants of clinical response to Sonidegib in advanced basal cell carcinoma: a monocenter experience.
Spallone G; Carbone A; Sperati F; Frascione P; Eibenschutz L
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(7):2923-2928. PubMed ID: 38639529
[TBL] [Abstract] [Full Text] [Related]
2. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
[TBL] [Abstract] [Full Text] [Related]
3. Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation.
Liu Q; Adhikari E; Lester DK; Fang B; Johnson JO; Tian Y; Mockabee-Macias AT; Izumi V; Guzman KM; White MG; Koomen JM; Wargo JA; Messina JL; Qi J; Lau EK
Nat Commun; 2024 Feb; 15(1):1148. PubMed ID: 38326303
[TBL] [Abstract] [Full Text] [Related]
4. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
[TBL] [Abstract] [Full Text] [Related]
5. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR; Di Giacomo AM; Caruso FP; Covre A; Mortarini R; Scala G; Costa MC; Coral S; Fridman WH; Sautès-Fridman C; Brich S; Pruneri G; Simonetti E; Lofiego MF; Tufano R; Bedognetti D; Anichini A; Maio M; Ceccarelli M
Nat Commun; 2023 Sep; 14(1):5914. PubMed ID: 37739939
[TBL] [Abstract] [Full Text] [Related]
6. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract] [Full Text] [Related]
7. Association of clinical manifestations of secondary lymphedema and lymph node dissection sites in the lower extremities of patients with melanoma.
Chae Woon P; Kim I; Kim JH; Hwang JH
Acta Oncol; 2023 Aug; 62(8):880-888. PubMed ID: 37656769
[TBL] [Abstract] [Full Text] [Related]
8. Molecular Features of Resected Melanoma Brain Metastases, clinical outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract] [Full Text] [Related]
9. Effect of lidocaine spray on reliving non-coring needle puncture-related pain in patients with totally implantable venous access port: a randomized controlled trial.
Zhu Y; Niu S; Zhang Y; Zhang H; Chang J; Ye L
Support Care Cancer; 2023 Jul; 31(8):452. PubMed ID: 37421451
[TBL] [Abstract] [Full Text] [Related]
10. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial.
Kent P; Haines T; O'Sullivan P; Smith A; Campbell A; Schutze R; Attwell S; Caneiro JP; Laird R; O'Sullivan K; McGregor A; Hartvigsen J; Lee DA; Vickery A; Hancock M;
Lancet; 2023 Jun; 401(10391):1866-1877. PubMed ID: 37146623
[TBL] [Abstract] [Full Text] [Related]
11. Predictive value and accuracy of [
Ayati N; Jamshidi-Araghi Z; Hoellwerth M; Schweighofer-Zwink G; Hitzl W; Koelblinger P; Pirich C; Beheshti M
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2715-2726. PubMed ID: 37140669
[TBL] [Abstract] [Full Text] [Related]
12. Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions.
De Falco V; Suarato G; Napolitano R; Argenziano G; Famiglietti V; Amato A; Servetto A; Bianco R; Formisano L; Terrano V; Esposito A; Giugliano MC; Ciardiello D; Ciardiello F; Napolitano S; Troiani T
Int J Cancer; 2023 Jul; 153(1):133-140. PubMed ID: 36752579
[TBL] [Abstract] [Full Text] [Related]
13. Characterization and dynamics of the soluble immunological microenvironment in melanoma patients undergoing radiotherapy.
Oertel M; Borrmann K; Baehr A; Eich HT; Greve B
Radiat Oncol; 2022 Nov; 17(1):194. PubMed ID: 36443849
[TBL] [Abstract] [Full Text] [Related]
14. Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts.
Konaté MM; Li MC; McShane LM; Zhao Y
Sci Rep; 2022 Nov; 12(1):19283. PubMed ID: 36369472
[TBL] [Abstract] [Full Text] [Related]
15. The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers.
Gaitanis G; Zampeta A; Tsintzou P; Fillis G; Seretis K; Feldmeyer L; Bassukas I
Curr Oncol; 2022 Nov; 29(11):8475-8482. PubMed ID: 36354728
[TBL] [Abstract] [Full Text] [Related]
16. clinical management of melanocytic tumours of uncertain malignant potential (MelTUMPs), including melanocytomas: A systematic review and meta-analysis.
Varey AHR; Williams GJ; Lo SN; Taing CY; Maurichi A; Santinami M; Scolyer RA; Thompson JF
J Eur Acad Dermatol Venereol; 2023 May; 37(5):859-870. PubMed ID: 36251355
[TBL] [Abstract] [Full Text] [Related]
17. A cohort analysis of surgically treated primary head and neck lentigo maligna (melanoma): Prognostic value of melanoma subtype and new insights in the clinical value of guideline adherence.
Elshot YS; Zupan-Kajcovski B; Ouwerkerk W; Klop WMC; Lohuis PJFM; Bol M; Crijns MB; Bekkenk MW; de Rie MA; Balm AJM
Eur J Surg Oncol; 2023 Apr; 49(4):818-824. PubMed ID: 36031471
[TBL] [Abstract] [Full Text] [Related]
18. Short-term and long-term outcomes of indocyanine green for sentinel lymph node biopsy in early-stage breast cancer.
Hua B; Li Y; Yang X; Ren X; Lu X
World J Surg Oncol; 2022 Aug; 20(1):253. PubMed ID: 35941602
[TBL] [Abstract] [Full Text] [Related]
19. Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial.
Lian B; Si L; Chi ZH; Sheng XN; Kong Y; Wang X; Tian H; Li K; Mao LL; Bai X; Tang BX; Yan XQ; Li SM; Zhou L; Dai J; Tang XW; Ran FW; Yao S; Guo J; Cui CL
Ann Oncol; 2022 Oct; 33(10):1061-1070. PubMed ID: 35842199
[TBL] [Abstract] [Full Text] [Related]
20. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C
ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748
[TBL] [Abstract] [Full Text] [Related]
[Next]
